Soleno Therapeutics: The biopharmaceutical company receives important FDA approval for a drug to treat a rare genetic disorder

Soleno is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. With the FDA approval of VYKAT XR, a novel therapy for hyperphagia in patients with Prader-Willi syndrome aged four and older, the company has achieved an important milestone. Soleno is well-positioned due to the lack of competition in treating the hyperphagia associated with the syndrome. Soleno Therapeutics (NASDAQ: SLNO), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics...